Vardenafil: Update on clinical experience

International Journal of Impotence Research

Volumn 14, Issue , 2002, Pages S65-S69

  Pryor, J ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Erectile dysfunction; Phosphodiesterase; Vardenafil

Indexed keywords

PHOSPHODIESTERASE INHIBITOR; PLACEBO; VARDENAFIL;

CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HUMAN; MALE; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RHINITIS; TREATMENT OUTCOME;

CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HUMANS; IMIDAZOLES; IMPOTENCE; MALE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; SULFONES; TRIAZINES;

EID: 0036193167     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/sj.ijir.3900796     Document Type: Article

References (10)

1. Bischoff E et al. Vardenafil a potent and selective inhibitor of phosphodiesterase type 5 increases cGMP in rabbit corpus cavemosum. Int J Impot Res 2000; 12(Suppl 3): S65.
2. Bischoff E et al. The oral efficacy of vardenafil hydrochloride in a conscious rabbit model. J Urol 2001; 165: 1316-1318.
3. Bischoff E, Schneider K. A conscious-rabbit model to study vardenafil hydrochloride and other agents that influence penile erection. Int J Impot Res 2001; 13: 230-235.
4. R and pharmacokinetic study. World J Urol 2001; 19: 32-39.
5. Stark S et al. Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur Urol 2001; 40: 181-188.
6. Porst H et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001; 13: 192-199.
7. Rosen RC et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-830.
8. Fugl-Meyer AR. On life satisfaction in male erectile dysfunction. Int J Impot Res 1997; 9: 141-148.
9. Young J et al. Vardenafil (a new selective PDE5 inhibitor) significantly improved all IIEF domains in patients with erectile dysfunction and showed a favourable safety profile: results at 4 and 12 weeks of treatment Paper presented at the American Urological Association Meeting, Anaheim, California, 2001.
10. Goldstein I et al. Vardenafil, a new highly selective PDE5 inhibitor, improves erectile function in patients with diabetes mellitus. Poster presented at the American Diabetic Association Meeting, Philadelphia, Pennsylvania, June 2001.